Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery

Cochrane Database of Systematic Reviews

Volumn 2021, Issue 11, 2021, Pages

  Legg, Lynn A ^a   Rudberg, Ann Sofie ^b   Hua, Xing ^c   Wu, Simiao ^c   Hackett, Maree L ^d   Tilney, Russel ^e   Lindgren, Linnea ^f   Kutlubaev, Mansur A ^g   Hsieh, Cheng Fang ^h   Barugh, Amanda J ⁱ   Hankey, Graeme J ^j   Lundström, Erik ^f   Dennis, Martin ^k   Mead, Gillian E ^k  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SICHUAN UNIVERSITY   (China)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e MATER DEI HOSPITAL   (Malta)

^f UPPSALA UNIVERSITY   (Sweden)

^g BASHKIR STATE MEDICAL UNIVERSITY   (Russian Federation)

^h KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ UNIVERSITY OF EDINBURGH   (United Kingdom)

^j UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^k UNIVERSITY OF EDINBURGH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADVERSE EVENT; ANXIETY; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; CLINICAL PRACTICE; CLINICAL RESEARCH; COCHRANE LIBRARY; COGNITION; COMPARATIVE STUDY; DEATH; DEMOGRAPHY; DEPRESSION; DISABILITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; EVIDENCE BASED MEDICINE; FATIGUE; FOLLOW UP; FRACTURE; GASTROINTESTINAL SYMPTOM; GRADE APPROACH; HEALTH CARE COST; HUMAN; INDEPENDENCE; INTERVENTION STUDY; META ANALYSIS; MOTOR DYSFUNCTION; NEUROLOGICAL DEFICIT SCORE; PREFERRED REPORTING ITEMS FOR SYSTEMATIC REVIEWS AND META-ANALYSES; PUBLICATION BIAS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SENSITIVITY ANALYSIS; SIDE EFFECT; STROKE SURVIVOR; SYSTEMATIC REVIEW; ANXIETY DISORDER;

ANXIETY; ANXIETY DISORDERS; FLUOXETINE; HUMANS; SEROTONIN UPTAKE INHIBITORS; STROKE;

EID: 85119157148     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009286.pub4     Document Type: Review

References (219)

1. Acler M, Avesani A, Fiaschi A, Manganotti P. Serotonergic modulation of brain excitability and motor recovery in patients affected by stroke. A double blind placebo RCT. International Journal of Stroke 2008;3:336. x-wiley/crsRef/3081365
2. Acler M, Robol E, Fiaschi A, Manganotti P. A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. Journal of Neurology 2009;256(7):1152-8. x-wiley/crsRef/3081366
3. ACTRN12611000774921. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011). x-wiley/crsRef/17962373
4. ACTRN12619000986178. The assessment of fluoxetine in stroke recovery imaging and blood biomarkers sub-study AFFINITY BM. www.anzctr.org.au/Trial/Registration/TrialReview.aspx ?ACTRN=12619000986178 (first received 11 July 2019). x-wiley/crsRef/17962374
5. AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology 2020;19(8):651-60. x-wiley/crsRef/17962371
6. Hankey G. Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019). x-wiley/crsRef/17962372
7. Almeida OP, Waterreus A, Hankey GJ. Preventing depression after stroke: results from a randomized placebo-controlled trial. Journal of Clinical Psychiatry 2006;67(7):1104-9. x-wiley/crsRef/3081368
8. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of post-stroke depression with selective serotonin reuptake inhibitors. Journal of Neurology 1994;241:S42. x-wiley/crsRef/3081370
9. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of post-stroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994;25(6):1099-104. x-wiley/crsRef/3081371
10. Andersen G, Vestergaard K, Lauritzen L. Post-stroke depression treated with citalopram. Acta Neurologica Scandinavica 1994;89 Suppl 155:20. x-wiley/crsRef/3081374
11. Andersen G, Vestergaard K, Lauritzen L. Post-stroke depression treated with citalopram - a selective serotonin reuptake inhibitor. Canadian Journal of Neurological Sciences 1993;20:S115. x-wiley/crsRef/3081372
12. Andersen G, Vestergaard K, Lauritzen L. Post-stroke depression treated with citalopram a selective serotonin reuptake inhibitor. In: 7th Scandinavian Meeting on Cerebrovascular Disease. 1993:54. x-wiley/crsRef/3081373
13. Andersen G, Vestergaard K, Lauritzen LU. Effective treatment of depression following apoplexy with citalopram. Ugeskrift for Laeger 1995;157(14):2000-3. x-wiley/crsRef/3081375
14. Flicker C, Andersen G, Bayer L. A placebo controlled study of citalopram treatment for post-stroke depression. In: 11th Annual Meeting of the American Association for Geriatric Psychiatry. 1998. x-wiley/crsRef/3081376
15. Andersen G. The efficacy of citalopram treatment in acute stroke (TALOS). www.clinicaltrials.gov/ct2/show/NCT01937182 (first received 9 September 2013). x-wiley/crsRef/17962375
16. Damsbo AG, Mortensen JK, Kraglund KL, Johnsen SP, Andersen G, Blauenfeldt RA. Prestroke physical activity and poststroke cognitive performance. Cerebrovascular Diseases 2020;49(6):632-8. x-wiley/crsRef/17962376
17. Kraglund KL, Mortensen JK, Damsbo AG, Modrau B, Simonsen SA, Iversen, HK, et al. Neuroregeneration and vascular protection by citalopram in acute ischemic stroke (TALOS). Stroke 2018;49(11):2568-76. x-wiley/crsRef/17962377
18. Kraglund KL, Mortensen JK, Damsbo AG, Modrau B, Simonsen SA, Iversen HK, et al. Neuroregeneration and vascular protection by citalopramin in acute ischemic stroke (TALOS). Stroke 2018;49(11):2568-76. x-wiley/crsRef/12305828
19. Kraglund KL, Mortensen JK, Grove EL, Johnsen SP, Andersen G. TALOS: a multicenter, randomised, double blind, placebo controlled trial to test the effects of citalopram in patients with acute stroke; protocol. International Journal of Stroke 2015;10:985-87. x-wiley/crsRef/17962378
20. Kraglund KL, Mortensen JK, Johnsen SP, Andersen G, Grove EL. Antiplatelet effects of citalopram in patients with ischaemic stroke: a randomized, placebo-controlled, double-blind study. Scientific Reports 2019;9(1):200482019. x-wiley/crsRef/17962379
21. Asadollahi M, Ramezani M, Khanmoradi Z, Karimialavijeh E. The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. Clinical Rehabilitation 2018;32(8):1069-75. x-wiley/crsRef/19264402
22. Bembenek JP, Niewada M, Klysz B, Mazur A, Kurczych K, Gluszkiewicz M, et al. Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial. Neurologia i Neurochirurgia Polska 2020;54(6):544-51. x-wiley/crsRef/17962381
23. Fluoxetine or control under supervision: Poland. Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products - EduraCT No: 2014-001335-37 2014. x-wiley/crsRef/17962382
24. Birchenall J, Térémetz M, Roca P, Lamy JC, Oppenheim C, Maier MA, et al. Individual recovery profiles of manual dexterity, and relation to corticospinal lesion load and excitability after stroke - a longitudinal pilot study. Neurophysiologie Clinique 2019;49(2):149-64. x-wiley/crsRef/12305832
25. NCT02063425. Evaluation by transcranial magnetic stimulation of the benefit of fluoxetine on motor recovery after stroke (EFLUSTIM). clinicaltrials.gov/ct2/show/NCT02063425 (first received 14 February 2014). x-wiley/crsRef/12305833
26. Brown KW, Sloan RL, Pentland B. Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica 1998;98(6):455-8. x-wiley/crsRef/3081378
27. Burns A, Russell E, Stratton-Powell H, Tyrell P, O'Neill P, Baldwin R. Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry 1999;14(8):681-5. x-wiley/crsRef/3081380
28. Cao JX, Liu L, Sun YT, Zeng QH, Wang Y, Chen JC. Effects of the prophylactic use of escitalopram on the prognosis and the plasma copeptin level in patients with acute cerebral infarction. Brazilian Journal of Medical and Biological Research 2020;53(11):e8930. x-wiley/crsRef/17962384
29. Cao JX, Liu L, Sun YT, Zeng QH, Yang ZD, Chen JC. Escitalopram improves neural functional prognosis and endothelial dysfunction in patients with acute cerebral infarction. Restorative Neurology and Neuroscience 2020;38(5):385-93. x-wiley/crsRef/17962385
30. Chen WY, Liu FY, Yang AP. Study of effect of integrative Chinese herbs with fluoxetine on rehabilitation of neurological impairment in patients with post-stroke depression. Journal of Chengdu University of Traditional Chinese Medicine 2001;24(4):20-3. x-wiley/crsRef/3081382
31. Chen W, Wang G-F, Chen X-H, Sheng Y-L, Zhu H. Effects of paroxetine on function recovery in patients with post-stroke depression. Chinese Journal of Clinical Rehabilitation 2002;6(13):2014-5. x-wiley/crsRef/3081384
32. Chen KN. Changes of neurotransmitter in patients with post-stroke depression observed with encephalofluctuography technology. Chinese Journal of Clinical Rehabilitation 2005;9(16):118-9. x-wiley/crsRef/12305837
33. Chen T, Li J, Han M. A study on paroxetine in the treatment for post-stroke depression. Jiangxi Medicine 2005;40(7):382-4. x-wiley/crsRef/12305839
34. Chen Z, Xu X, Wu Y, Huang L. Clinical efficacy of drug intervention in patients with acute depression after stroke. International Journal of Psychiatry 2015;42(5):97-100. x-wiley/crsRef/17962387
35. Cheng F, Shao G, Bao S. Study of effect on neurologic function rehabilitation in patient with post-stroke depression. Chinese Journal of Clinical Rehabilitation 2003;7(1):108-9. x-wiley/crsRef/3081386
36. Chollet F, Tardy J, Albucher J-F, Thalamas E, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurology 2011;10(2):123-30. x-wiley/crsRef/3081392
37. Dam M, Tonin P, De Boni A, Pizzolato G, Casson S, Ermani M, et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke 1996;27(7):1211-4. x-wiley/crsRef/3081394
38. Dike F. Pharmacological enhancement of motor function recovery in patients with ischaemic stroke: a trial of fluoxetine. www.pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=967 (last accessed 16 February 2021). x-wiley/crsRef/17962389
39. Dike FO, Ekeh BC, Ogun AS, Ekrikpo EU, Walshak P, Ogunniy AA. Pharmacological enhancement of motor function recovery in patients with ischaemic stroke: a trial of fluoxetine. Journal of Neurology and Stroke 2019;9(1):47-51. x-wiley/crsRef/17962388
40. EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology 2020;19(8):661-9. x-wiley/crsRef/19018227
41. ISRCTN13020412. Establishing the effect(s) and safety of fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ISRCTN13020412 (first received 19 December 2014). x-wiley/crsRef/19018228
42. Lundström E, Isaksson E, Näsman P, Wester P, Mårtensson B, Norrving B. Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials 2020;21(388):s13063-020-04327-w. x-wiley/crsRef/19018229
43. Lundström E, Isaksson E, Näsman P et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials 2020;21(233):s13063-020-4124-7. x-wiley/crsRef/19018230
44. Lundstrom E, Isaksson E, Nasman P, Wester P, Martensson B, Norrving B, et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology 2020;19(8):661-9. x-wiley/crsRef/19018231
45. Feng B-L, Wang Q-C, Zheng-Yuan LI. Influence of Jieyu Huoxue decoction on rehabilitation of patients with depression after cerebral infarction. Journal of Chinese Integrated Medicine 2004;2(3):182-4. x-wiley/crsRef/3081396
46. Anonymous. The FOCUS (Fluoxetine or Control under Supervision) trial results: effects of a 6 month course of fluoxetine on the Stroke Impact Scale, mood and fatigue in patients with stroke. www.ed.ac.uk/clinical-brain-sciences/research/completed-studies-trials/focus-stroke-trial (accessed 12 02 2021). x-wiley/crsRef/19264404
47. Cook R, Thomas V, Martin R. Does fluoxetine improve recovery after stroke? BMJ 2019;364:1029. x-wiley/crsRef/19264405
48. Dennis M, Forbes J, Graham C, Hackett M, Hankey GJ, House A, et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technology Assessment 2020;24(22):1-94. x-wiley/crsRef/19264406
49. Dennis M, Forbes J, Graham C, Hackett ML, Hankey GJ, House A, et al. Fluoxetine and fractures after stroke: exploratory analyses from the FOCUS Trial. Stroke 2019;50(11):3280-2. x-wiley/crsRef/19264407
50. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet 2019;393(10168):265-74. x-wiley/crsRef/19264408
51. Graham C, Lewis S, Forbes J, Mead G, Hackett ML, Hankey GJ, et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials 2017;18(1):627. x-wiley/crsRef/19264409
52. Lundstrom E, Dennis M, Mead G. The effects of fluoxetine on fracture risk after stroke: Further analyses from the focus trial. European Stroke Journal 2019;4 suppl 1:7142019. x-wiley/crsRef/19264410
53. Mead G, Dennis M. Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine or Control under Supervision (FOCUS) trial. BMJ Open 2020;10(11):e0404922020. x-wiley/crsRef/19264411
54. Mead G. Fluoxetine Or Control Under Supervision (FOCUS) trial: to establish the effect(s) of routine administration of Fluoxetine in patients with a recent stroke. www.isrctn.com/ISRCTN83290762 (first received 23 May 2012). x-wiley/crsRef/19264412
55. Mead GE, Dennis MS, Innes K, MacLeod M, Sandercock PA, House A, et al. A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (Fluoxetine Or Control Under Supervision, FOCUS). In: 21st European Stroke Conference. 2012:Abst OAID 26. x-wiley/crsRef/19264413
56. Mead GE, Graham C, Billot L, Näsman P, Lundström E, Lewis S, on behalf of the FOCUS, AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials 2020;21(1):971. x-wiley/crsRef/19264414
57. Mead GE, Legg L, Tilney R, Hsieh CF, Wu S, Lundström E, et al. Fluoxetine for stroke recovery: meta-analysis of randomized controlled trials. International Journal of Stroke 2020;15(4):365-76. x-wiley/crsRef/19264415
58. Fruehwald S, Gatterbauer E, Rehak P, Baumhackl U. Early fluoxetine treatment of post-stroke depression: a three-month double-blind placebo-controlled study with an open-label long-term follow up. Journal of Neurology 2003;250(3):347-51. x-wiley/crsRef/3081400
59. Gao J, Lin M, Zhao J, Bi S, Ni Z, Shang X. Different interventions for post-ischaemic stroke depression in different time periods: a single-blind randomized controlled trial with stratification by time after stroke. Clinical Rehabilitation 2017;31(7):71-81. x-wiley/crsRef/17962410
60. GlaxoSmithKline. An 8-week double-blind placebo controlled parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from depression following stroke. GSK Clinical Study Register www.gsk clinicalstudyregister.com (accessed 31 August 2012). x-wiley/crsRef/3081402
61. Gong L, Yang X, Feng Y, Fei Z, Wang M, Qin B, et al. The efficacy of integrative anti-depressive therapy on motor recovery after ischemic stroke: a randomized clinical trial. European Journal of Integrative Medicine 2020;35:101102. x-wiley/crsRef/17962412
62. Guo R-Y, Su L, Wang CX. Effects of Linggui Bafa on the therapeutic effect and quality of life in patients of post-stroke depression. Chinese Acupuncture & Moxibustion 2009;29(10):785-90. x-wiley/crsRef/3081404
63. He P. Randomized controlled observation on the effect of early application of fluoxetine in preventing depression after stroke. Chinese Journal of Clinical Rehabilitation 2004;8(28):6016-7. x-wiley/crsRef/3081406
64. He Y, Wang X, Xiao C. Prospective study of effects of paroxetine with mental intervention on depression and anxiety after stroke. Nervous Diseases and Mental Health 2005;5(1):6-13. x-wiley/crsRef/3081408
65. Wang X, He Y, Xiao C-L. A clinical trial of paroxetine and psychotherapy in patients with post-stroke depression and anxiety. Chinese Mental Health Journal 2005;19:564-6. x-wiley/crsRef/3081409
66. ChiCTR-TRC-12002078. Multi-center randomized clinical study of antidepressant treatment (fluoxetine) on secondary prevention of ischemic stroke. www.chictr.org.cn/showprojen.aspx?proj=7471 (first received 3 April 2012). x-wiley/crsRef/17962413
67. Guo Y, He Y, Tang B, Ma K, Cai Z, Zeng S, et al. Effect of using fluoxetine at different time windows on neurological functional prognosis after ischaemic stroke. Restorative Neurology and Neuroscience 2016;34:177-87. x-wiley/crsRef/17962414
68. He Y, Cai Z, Zeng S, Chen S, Tang B, Liang Y, et al. Effect of fluoxetine on three-year recurrence in acute ischemic stroke: a randomized controlled clinical study. Clinical Neurology and Neurosurgery 2018;168:1-6. x-wiley/crsRef/17962415
69. He Y-T, Tang B-S, Cai Z-L, Zeng S-L, Jiang X, Guo Yi. Effects of fluoxetine on neural functional prognosis after ischemic stroke: a randomized controlled study in China. Journal of Stroke and Cerebrovascular Diseases 2016;25(4):761-70. x-wiley/crsRef/12305848
70. Hu Y, Suo A, Xiang L. The comparative study of the effectiveness of fluoxetine on the stroke patients with depressive symptoms. Shanghai Archives of Psychiatry 2002;14:149-50. x-wiley/crsRef/3081411
71. Hu H, Wang M. Effects of escitalopram on post-stroke depression and cognitive function of patients with neurological function. Hebei Medicine 2018;24(2):325-8. x-wiley/crsRef/17962417
72. Huang X-H. The clinical correlation study and the effect of fluoxetine intervention on poststroke depression. Chinese Journal of Clinical Rehabilitation 2002;6(15):2296-7. x-wiley/crsRef/3081413
73. Jia W. Effect of early intervention on recovery of motor function and recurrent stroke in patients with post-stroke depression. Chinese Journal of Clinical Rehabilitation 2005;9(12):4-5. x-wiley/crsRef/3081417
74. Kim JS, Lee E-J, Chang D-ll, Park J-H, Ahn SH, Cha J-K, et al. Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Psychiatry 2017;4(1):33-41. x-wiley/crsRef/19264417
75. Lee EJ, Kim JS, Chang DI, Park JH, Ahn SH, Cha JK, et al. Differences in therapeutic responses and factors affecting post-stroke depression at a later stage according to baseline depression. Journal of Stroke 2018;20(2):258-67. x-wiley/crsRef/19264418
76. Lee EJ, Kim JS, Chang DI, Park JH, Ahn SH, Cha JK, et al. Post-stroke depressive symptoms: varying responses to escitalopram by individual symptoms and lesion location. Journal of Geriatric Psychiatry and Neurology 2020;10:891988720957108. x-wiley/crsRef/19264419
77. Lee EJ, Oh MS, Kim JS, Chang DI, Park JH, Cha JK, EMOTION investigators. Serotonin transporter gene polymorphisms may be associated with poststroke neurological recovery after escitalopram use. Journal of Neurology, Neurosurgery and Psychiatry 2018;89(3):271-6. x-wiley/crsRef/19264420
78. NCT01278498. The preventative effect of escitalopram on depression and related emotional disorders in acute stroke patients, 2011. clinicaltrials.gov/ct2/show/NCT01278498 (first received 19 January 2011). x-wiley/crsRef/19264421 [NCT01278498]
79. Kong Y. Fluoxetine for poststroke depression: a randomized placebo controlled clinical trial. Neural Regeneration Research 2007;2(3):162-5. x-wiley/crsRef/3081419
80. Lai J. The effect of using paroxetine to treat post stroke depression. Journal of Guangdong Medical College 2006;24(6):585-6. x-wiley/crsRef/3081421
81. Li J, He Q-Y, Han M-F. Recent effect of fluoxetine in improving neurologic impairment and preventing post-stroke depression in the early stage. Chinese Journal of Clinical Rehabilitation 2004;8(7):1208-9. x-wiley/crsRef/3081425
82. Li C-M, Jiang X-D, Liao G, Lei J-M, Lan S, Ni F-W. Effect of antidepressant drugs in early period on the recovery of post-stroke depression. Chinese Journal of Clinical Rehabilitation 2004;8(19):3713-5. x-wiley/crsRef/3081427
83. Li Y, Wang X, Qian FS. Related factors of post-stroke depression and effect of paroxetine. Shandong Archives of Psychiatry 2005;18(4):209-10. x-wiley/crsRef/3081429
84. Li W-Q, Li D-X. The efficacy of citalopram for post-stroke depression and its effects on stroke rehabilitation. International Journal of Cerebrovascular Diseases 2006;14(4):275-8. x-wiley/crsRef/3081431
85. Li Z. Clinical efficacy of paroxetine in the treatment of post-stroke depression. Modern Journal of Integrated Traditional Chinese and Western Medicine 2007;16(34):5103-4. x-wiley/crsRef/17962425
86. Li L-T, Wang S-H, Ge H-Y, Chen J, Yue S-W, Yu M. The beneficial effects of the herbal medicine free and easy wanderer plus (FEWP) and fluoxetine on post-stroke depression. Journal of Alternative and Complementary Medicine 2008;14(7):841-6. x-wiley/crsRef/3081433
87. Li J, Wang J, Li Y, Zhang W, Zhao J. Effects of escitalopram oxalate on post-stroke depression, cognition and neurological function. Journal of Hebei Medical University 2017;38(5):589-92. x-wiley/crsRef/17962427
88. Liu Y, Xu R. Effect of citalopram treatment on post-stroke depression and neurological functional rehabilitation. Chinese Journal of Rehabilitation 2006;21(3):174-5. x-wiley/crsRef/3081439
89. Marquez-Romero JM, Arauz A, Ruiz-Sandoval JL, Cruz-Estrada Ede L, Huerta-Franco MR, Aguayo-Leytte G, et al. Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebo-controlled, multicenter trial. Trials 2013;14:77. x-wiley/crsRef/17962428
90. Marquez-Romero JM, Reyes-Martínez M, Huerta-Franco MR, Ruiz-Franco A, Silos H, Arauz A. Fluoxetine for motor recovery after acute intracerebral hemorrhage, the FMRICH trial. Clinical Neurology and Neurosurgery 2020;190:105656. x-wiley/crsRef/17962429
91. Marquez-Romero JM, Reyes-Martínez M, Huerta-Franco MR, Ruiz-Franco A, Silos H, Arauz A. Fluoxetine for motor recovery after acute intracerebral hemorrhage, the FMRICH Trial. Correspondence from Marquez-Romero 2018. x-wiley/crsRef/12305854
92. Marquez-Romero JM. Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH). www.clinicaltrials.gov/ct2/show/NCT01737541 (first received 29 November 2012). x-wiley/crsRef/12305855
93. Meara RJ, Thalanany M, Balonwu V, Hobson P. The treatment of depression after stroke with the selective serotonin reuptake inhibitor sertraline. Cerebrovascular Diseases 1998;8 Suppl 4:90. x-wiley/crsRef/3081441
94. Miao S-Y, Shi Y-J. Related factors of post-stroke depression and therapeutical effect of citalopram. Chinese Journal of Clinical Rehabilitation 2004;8(19):3718-9. x-wiley/crsRef/3081443
95. Murray V, Von Arbin M, Bartfai A, Berggren A-L, Landtblom A-M, Lumdmark J, et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry 2005;66(6):708-16. x-wiley/crsRef/3081445
96. NCT00177424. Setraline for prevention post stroke depression and improving rehabilitation outcomes. clinicaltrials.gov/ct2/show/NCT00177424 (first received 15 September 2005). x-wiley/crsRef/19018246
97. NCT01674868. Fluoxetine for motor, aphasia, and neglect recovery after ischemic stroke (FLAN). www.clinicaltrials.gov/ct2/show/NCT01674868 (first received 29 August 2012). x-wiley/crsRef/19018248
98. NCT02737930. Fluoxetine for visual recovery after ischaemic stroke (FLUORESCE). www.clinicaltrials.gov/ct2/show/NCT02737930 (first received 14 April 2016). x-wiley/crsRef/19018250
99. Pan X-L, Chen H-F, Cheng X, Hu C-C, Wang J-W, Fu Y-M, et al. Effects of paroxetine on motor and cognitive function recovery in patients with non-depressed ischemic stroke: an open randomized controlled study. Brain Impairment;doi: 10.1017/BrImp.2018.6. x-wiley/crsRef/12305857
100. Guiraud-Chaumeil B, Pariente J, Albucher J-F, Loubinoux I, Chollet F. Rehabilitation after stroke [Recuperation neurologique post-ischemique]. Bulletin de l'Académie Nationale de Médecine 2002;6:1015-24. x-wiley/crsRef/3081447
101. Pariente J, Loubinoux I, Carel C, Albucher JF, Leger A, Manelfe C, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Annals of Neurology 2001;50(6):718-29. x-wiley/crsRef/3081448
102. Rasmussen A, Lunde M, Poulsen D, Sørensen K, Qvitzau S, Bech P. A double-blind placebo controlled study of sertraline in the prevention of depression in stroke patients. European Neuropyschopharmacology 2002;12:231. x-wiley/crsRef/3081450
103. Rasmussen A, Lunde M, Poulsen DL, Sørensen K, Qvitzau S, Bech P. A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics 2003;44(3):216-22. x-wiley/crsRef/3081451
104. Rasmussen A. Depression and stroke. Nordic Journal of Psychiatry 2001;55(4):288. x-wiley/crsRef/3081452
105. Rasmussen A. Prophylactic treatment for post-stroke depression and comorbidity. Journal of Psychosomatic Research 2000;48(3):66. x-wiley/crsRef/3081453
106. Razazian N, Esmaeili O, Almasi A. Effect of fluoxetine on motor improvement in ischemic stroke patients: a double blind clinical trial study. Zahedan Journal of Research in Medical Sciences 2016;18(7):e75492016. x-wiley/crsRef/17962430
107. Razazian N. A survey for assessment of effectiveness of fluoxetine on motor improvement in ischemic stroke patients. www.en.irct.ir/trial/8797 (first received 9 January 2014). x-wiley/crsRef/12305859
108. Restifo DA, Lo Prest R, Lanza S, Giuffrida S, D'Aleo G, Rifici Di Bella C, et al. Motor cortex reorganization induced by fluoxetine in poststroke hemiplegic patients undergoing rehabilitation therapy: a study with transcranial magnetic stimulation. Neurorehabilitation and Neural Repair 2001;15(4):284. x-wiley/crsRef/3081455
109. Jorge RE, Robinson RG, Arndt S, Starkstein S. Mortality and post-stroke depression: a placebo controlled trial of antidepressants. American Journal of Psychiatry 2003;160:1823-9. x-wiley/crsRef/3081457
110. Narushima K, Kosier JT, Robinson RG. Preventing post-stroke depression: a 12 week double blind randomised treatment trial and 21 month follow-up. Journal of Nervous and Mental Diseases 2002;190:296-303. x-wiley/crsRef/3081458
111. Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. American Journal of Psychiatry 2000;157(3):351-9. x-wiley/crsRef/3081459
112. Jorge RE, Robinson RG, Arndt S, Starkstein S. Mortality and post-stroke depression: a placebo controlled trial of antidepressants. American Journal of Psychiatry 2003;160:1823-9. x-wiley/crsRef/3081461
113. Narushima K, Robinson RG. Preventing post-stroke depression: a 12 week double blind randomised treatment trial and 21 month follow-up. Journal of Nervous and Mental Diseases 2002;190:296-303. x-wiley/crsRef/3081462
114. Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. American Journal of Psychiatry 2000;157(3):351-9. x-wiley/crsRef/3081463
115. Jorge RE, Acion L, Moser D, Adams HP, Robinson RG. Escitalopram and enhancement of cognitive recovery following stroke. Archives of General Psychiatry 2010;67(2):187-96. x-wiley/crsRef/3081465
116. Robinson RG, Arndt S. Incomplete financial disclosure in a study of escitalopram and problem solving therapy for prevention of post-stroke depression. JAMA 2009;301:1023-4. x-wiley/crsRef/3081466
117. Robinson RG, Jorge RE, Moser DJ, Acion L, Solodkin A, Small SL, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression. JAMA 2008;299(20):2391-400. x-wiley/crsRef/3081467
118. Savadi Oskouie D, Sharifipour E, Sadeghi Bazargani H, Hashemilar M, Nikanfar M, Ghazanfari Amlashi S, et al. Efficacy of citalopram on acute ischemic stroke outcome: a randomized clinical trial. Neurorehabilitation and Neural Repair 2017;31(7):638-47. x-wiley/crsRef/12305861
119. Savadi Oskouie D. Evaluation of the effect of citalopram on three months functional prognosis of acute ischemic stroke patients: a randomized clinical trial. www.en.irct.ir/trial/1766 (first received 22 April 2012). x-wiley/crsRef/12305862
120. Shah IA, Asimi RP, Kawoos Y, Wani MA, Wani MA, Dar MA. Effect of fluoxetine on motor recovery after acute haemorrhagic stroke: a randomized trial. Journal of Neurology and Neurophysiology 2016;7(2). x-wiley/crsRef/12305864 [DOI: 10.4172/2155-9562.1000364]
121. Song J-G. Effects of fluoxetine hydrochloride on depressive symptoms and P300 after cerebral stroke. Chinese Journal of Clinical Rehabilitation 2006;10(14):160-2. x-wiley/crsRef/3081469
122. Wang X, Tan Z, Wu Z, Gao J, Feng M. The effects of anti-depression therapy on post-stroke depression and neurologic rehabilitation in the elderly patients. Chinese Journal of Geriatrics 2003;22(5):270-3. x-wiley/crsRef/3081471
123. Wang X. The efficacy of paroxetine in the treatment of post-stroke depression in 55 cases. Chinese Community Physician (Medical Professional Half-monthly) 2009;11(7):11. x-wiley/crsRef/17962432
124. Wen Z-X. The influence of post-stroke prophylactic anti-depression treatment on nerve functional rehabilitation. Acta Academiae Medicinae Qingdao Universitatis 2006;42(3):253-4. x-wiley/crsRef/3081473
125. Wiart L, Petit H, Joseph PA, Mazaux JM, Barat M. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 2000;31(8):1829-32. x-wiley/crsRef/3081475
126. Xie R, Liu J, Quan H. A prospective random clinical contrast study of treatment with sertraline in elderly patients with post-stroke depression. Chinese Journal of Clinical Neuroscience 2005;13(3):294-7. x-wiley/crsRef/3081477
127. Xu J, Tan J, Ou L. A study on treatment of fluoxetine to depression in early recovery stage of cerebral infarction. Chinese Journal of Rehabilitation Medicine 2001;16(5):281-3. x-wiley/crsRef/3081479
128. Xu J, Wang J, Liu J. Preventive effects of antidepressants on post-stroke depression. Chinese Mental Health Journal 2006;20(3):186-8. x-wiley/crsRef/3081481
129. Yang J, Zhao Y, Bai S. Controlled study on antidepressant treatment of patients with post-stroke depression. Chinese Mental Health Journal 2002;16(12):871-2. x-wiley/crsRef/3081485
130. Yang J. Therapeutic effect of paroxetine on patients with early poststroke depression and the serum interleukins. Chinese Journal of Cerebrovascular Diseases 2011;8(5):235-8. x-wiley/crsRef/3081487
131. Ye L-X, Wang H, Wang Y-D, Zhong L, Liang D-S, Guo Y. Effect of anti-depressive therapy on the rehabilitation of psychological and neurological function after stroke. Chinese Journal of Clinical Rehabilitation 2004;8(31):6826-8. x-wiley/crsRef/3081489
132. Ye LX. Effect of paxil and berhomine on post-stroke anxiety-depression and neurological recovery. Chinese Journal of Clinical Rehabilitation 2006;10(6):153-5. x-wiley/crsRef/3081490
133. Zhao P, Wang J-P. Effects of antidepressants on neurofunctional recovery of post-stroke patients with aphasia. Journal of Dalian Medical University 2011;33(1):55-7. x-wiley/crsRef/12305868
134. Zhou Z-l, Liang L-Z, Yan Y-X. Preventive effects of fluoxetine on post-stroke depression. Chinese Journal of Modern Applied Pharmacy 2008;25(3):263-4. x-wiley/crsRef/3081494
135. ACTRN12619000573156. FRAMBOISE: Fluoxetine, Recovery And Motor BiOmarkers In StrokE. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377306 (first received 11 April 2019). x-wiley/crsRef/19018252
136. Andersen G, Vestergaard K, Riis JO. Citalopram for post-stroke pathological crying. Lancet 1993;342(8875):837-9. x-wiley/crsRef/12305870
137. Andersen G. Efficacy of escitalopram treatment in acute stroke and the role of specific genotypes in stroke. www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005541-12 (first received 27 February 2012). x-wiley/crsRef/17962433
138. Andersen G. Escitalopram Treatment In Acute Stroke (ESTIAS). www.clinicaltrials.gov/ct2/show/NCT01561092 (first received 22 March 2012). x-wiley/crsRef/17962434
139. Anderson C, Hackett M, Carter K, Ni MC. Maximising outcome by overcoming depression in stroke (MOODS) trial. Cerebrovascular Diseases 2002 2002;13 Suppl 3:79. x-wiley/crsRef/12305874
140. Anonymous 2012. Stroke and depression. Johns Hopkins Medical Letter: Health After 50 2012;23(11):3. x-wiley/crsRef/19018254
141. Anonymous. Drug & Device News. Medical Malpractice Law & Strategy, New York Law Journal Newsletters 2012;30(2):5. x-wiley/crsRef/12305878
142. Berends HI, Nijlant JM, Putten MJ, Movig KL, IJzerman MJ. Single dose of fluoxetine increases muscle activation in chronic stroke patients. Clinical Neuropharmacology 2009;32(1):1-5. x-wiley/crsRef/12305880 [also known as Flu 2006]
143. Bonin Pinto C, Morales-Quezada L, de Toledo Piza PV, Zeng D, Saleh Vélez FG, Ferreira IS, et al. Combining fluoxetine and rTMS in poststroke motor recovery: a placebo-controlled double-blind randomized phase 2 clinical trial. Neurorehabilitation and Neural Repair 2019;33:643-55. x-wiley/crsRef/19264423 [DOI: 10.1177/1545968319860483.]
144. NCT02208466. Effects rTMS combined with fluoxetine on motor recovery in stroke patients. www.clinicaltrials.gov/ct2/show/NCT02208466 (first received 5 August 2014). x-wiley/crsRef/19264424
145. Chen Ma, Ping L. Effectiveness of paroxetine in the treatment of poststroke depression. Medicine 2018;97(29):1-4. x-wiley/crsRef/17962436
146. Choi-Kwon S, Choi J, Kwon SU, Kang DW, Kim JS. Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovascular Diseases 2008;26(3):266-71. x-wiley/crsRef/12305882
147. Finkenzeller W, Zobel I, Rietz S, Schramm E, Berger M. Interpersonal psychotherapy and pharmacotherapy for post-stroke depression. Feasibility and effectiveness. Der Nervenarzt 2009;80(7):805-12. x-wiley/crsRef/3081398
148. Foster E, Yaroslavtseva O, Chundamala J, Leibovitch F, Eng JJ, Ali F, et al. FLOW Trial: fluoxetine to open the critical period time window to improve motor recovery after stroke. International Journal of Stroke 2019;14 Suppl 3:36. x-wiley/crsRef/17962438
149. Gourab K, Schmit BD, Hornby GT. Increased lower limb spasticity but not strength or function following a single-dose serotonin reuptake inhibitor in chronic stroke. Archives of Physical Medicine and Rehabilitation 2015;96(12):2112-9. x-wiley/crsRef/12305884
150. Graffagnino C. Poststroke depression and functional recovery (SADBRAIN). Duke University Medical Centre 2002. x-wiley/crsRef/12305886
151. Ji QM, Xie LP. Efficacy of fluoxetine in the treatment of 20 patients with depression after stroke. Herald of Medicine 2000;19(4):329. x-wiley/crsRef/3081415
152. Dose-finding study of selective serotonin reuptake inhibitors to enhance neuroplasticity [Dose finding study but the intervention is a combination of an SSRI and paired associative stimulation, so we can exclude]. Source not provided from searches 2020. x-wiley/crsRef/17962441
153. Li F, Gu DX, Ceng SH, Xu JW. Effect of paroxetine on prognosis of patients with post cerebral infarction depression. Chinese Journal of New Drugs and Clinical Remedies. 2002;21(1):11-3. x-wiley/crsRef/3081423
154. Liang Z, Shuliang T. Clinical efficacy of fluoxetine in treatment of patients with depression after acute stroke. Chinese Journal of Clinical Rehabilitation 2003;7(13):1924-5. x-wiley/crsRef/3081435
155. Liu L-X. Recent effect of drug intervention on post-stroke anxiety. Chinese Journal of Clinical Rehabilitation 2004;8(30):6600-1. x-wiley/crsRef/3081437
156. Liu W, Ding W. Study on the efficacy and mechanism of paroxetine hydrochloride combined with repetitive transcranial magnetic stimulation in the treatment of post-stroke depression. International Journal of Clinical and Experimental Medicine 2020;13(10):7881-8. x-wiley/crsRef/17962443
157. Mosarrezaii A, Salmasi BA, Taghavi SA. Studying effect of fluoxetine on improvement of motor performance in patients with ischemic stroke. Journal of Research in Medical and Dental Sciences 2018;6(3):118-22. x-wiley/crsRef/17962445
158. NCT01963832. RCT of a neuroplasticity agent and CI therapy for severe arm paresis after stroke. clinicaltrials.gov/ct2/show/NCT01963832 (first received 16 October 2013). x-wiley/crsRef/19018256
159. Robinson RG, Mikami K, Jang M, Jorge RE. Prevention of anxiety disorder after stroke. Journal of Neuropsychiatry and Clinical Neurosciences 2011;23(2):18. x-wiley/crsRef/12305888
160. Sitzer M, Huff W, Steckel R. Prevention of poststroke depression after acute ischemic stroke using the selective serotonin reuptake inhibitor sertraline (PreDis-study). Stroke 2002;33(2):651-2. x-wiley/crsRef/12305890
161. Sun YT, Bao YH, Wang SL, Chu JM, Li LP. Efficacy observation on the treatment of post-stroke depression by acupuncture at the acupoints based on ziwuliuzhu and Prozac. Chinese Acupuncture and Moxibustion 2015;355(2):119-22. x-wiley/crsRef/12305892
162. Vogel AC, Okeng'o K, Chiwanga F, Ismail SS, Buma D, Pothier L. MAMBO: Measuring Ambulation, Motor, and Behavioral Outcomes with post-stroke fluoxetine in Tanzania: protocol of a phase II clinical trial. Journal of the Neurological Sciences 2020;408:116563. x-wiley/crsRef/17962451 [PMID: DOI:10.1016/j.jns.2019.116563]
163. Xu B, Zhou WY, Zhang SJ. Observation of effect of Wulung capsule in treating post-stroke depression. Chinese Journal of Integrated Traditional and Western Medicine 2007;27(7):640-2. x-wiley/crsRef/12305896
164. Zhou B. Effects of fluoxetine on neurofunctional recovery of non depressed patients after stroke. Chinese Journal of Clinical Rehabilitation 2003;7(3):374-5. x-wiley/crsRef/12305898
165. Guo Y, He Y, Tang B, Ma K, Cai Z, Zeng S, et al. Effect of using fluoxetine at different time windows on neurological functional prognosis after ischemic stroke. Restorative Neurology and Neuroscience 2016;34(2):177–87. x-wiley/crsRef/19018258
166. Guo Y. Effect of using fluoxetine at different time windows after ischemic stroke on neurological functional prognosis: a randomized controlled trial. chictr.org.cn/showprojen.aspx?proj=12925 (first received 27 December 2015). x-wiley/crsRef/19018259
167. ChiCTR-TRC-12002078. Multi-center randomized clinical study of antidepressant treatment (fluoxetine) on secondary prevention of ischemic stroke. www.chictr.org.cn/showprojen.aspx?proj=7471 (first received 3 April 2012). x-wiley/crsRef/19018261
168. He Y, Cai Z, Zeng S, Chen S, Tang B, Liang Y, et al. Effect of fluoxetine on three-year recurrence in acute ischemic stroke: a randomized controlled clinical study. Clinical Neurology and Neurosurgery 2018;168:1-6. x-wiley/crsRef/19018262
169. Jurcau A, Simion A. Improved post-ischaemic stroke recovery over 1 year with escitalopram for 3 months. European Journal of Neurology 2016;23:614. x-wiley/crsRef/12305906
170. NCT00967408. Effects of clinical and functional outcome of escitalopram in adult stroke patients. clinicaltrials.gov/ct2/show/NCT00967408 (first received 27 August 2009). x-wiley/crsRef/19018264 [NCT00967408]
171. ChiCTR1800019467. The effect and mechanism of fluoxetine on the automatic regulation of cerebral blood flow for ischemic stroke. https://www.chictr.org.cn/showprojen.aspx?proj=32801. x-wiley/crsRef/19018266
172. CTRI/2018/12/016568. An interventional study to look at efficacy of fluoxetine in patients with post-stroke anxiety. http://ctri.nic.in CTRI/2018/12/016568 (first received 10 December 2018). x-wiley/crsRef/19018268
173. EudraCT 2005-005266-37. Influence of escitalopram on the incidence of depression and dementia following acute middle cerebral artery territory infarction. A randomised placebo-controlled double blind study. www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005266-37 (first received 7 April 2006). x-wiley/crsRef/19018270
174. IRCT201112228490N1. Effect of fluoxetine on functional recovery of patients with cerebrovascular accident following middle cerebral artery trunk obstruction: a randomized clinical trial. www.en.irct.ir/trial/8954 (first received 25 January 2012). x-wiley/crsRef/19018272
175. IRCT2012101011062N1. A study of sertraline effect on quality of life in stroke inpatients. www.en.irct.ir/trial/11413 (first received 28 November 2012). x-wiley/crsRef/19018274
176. IRCT2017041720258N37. Evaluation of fluoxetine and standard treatment efficacy on change to side effect of stroke of ischemic strokes in both hemispheres in anterior circulation. www.irct.ir/trial/17976 (first received 11 October 2017). x-wiley/crsRef/19018276
177. IRCT20210307050617N1. The efficacy comparison of fluoxetine and citalopram on motor recovery after ischemic stroke: single-blind placebo-controlled randomized clinical trial. https://en.irct.ir/trial/54896 (first received 27 March 2021). x-wiley/crsRef/19018278
178. NCT02386475. Effect of serotonin and levodopa in ischemic stroke. www.clinicaltrials.gov/ct2/show/NCT02386475 (first received 12 March 2015). x-wiley/crsRef/19018280
179. NCT02767999. Serotonin Selective Reuptake Inhibitor (SSRI) effects on cerebral connectivity in acute ischemic stroke (RECONISE). www.clinicaltrials.gov/ct2/show/NCT02767999 (first received 11 May 2016). x-wiley/crsRef/19018282
180. NCT02865642. Cortical ischemic stroke and serotonin (CISS). www.clinicaltrials.gov/ct2/show/NCT02865642 (first received 12 August 2016). x-wiley/crsRef/19018284
181. NCT03448159. Fluoxetine Opens Window to improve motor recovery after stroke (FLOW). www.clinicaltrials.gov/ct2/show/NCT03448159 (first received 27 February 2018). x-wiley/crsRef/19018286
182. NCT03826875. Depression in hemorrhagic stroke. www.clinicaltrials.gov/ct2/show/NCT03826875 (first received 1 February 2019). x-wiley/crsRef/19018288
183. TCTR20181216001. Randomized controlled trial of fluoxetine or placebo on quality of life after acute ischemic stroke. www.thaiclinicaltrials.org/show/TCTR20181216001 (first received 16 December 2018). x-wiley/crsRef/19018290
184. Allida S, Patel K, House A, Hackett ML. Pharmaceutical interventions for emotionalism after stroke. Cochrane Database of Systematic Reviews 2019, Issue 3. Art. No: CD003690. [DOI: 10.1002/14651858.CD003690.pub4]
185. Deeks JJ, Higgins JP, Altman DG, editors. Chapter 10: Analysing data and performing metaanalyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al(editor s).), Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021) Cochrane 2021. Available at www.training.cochrane.org/handbook.
186. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
187. GBD 2015. Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study. Lancet 2016;388(10053):1545–602.
188. Schünemann H, Brożek J, Guyatt G, Oxman A, editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.
189. McMaster University (developed by Evidence Prime, Inc.) GRADEpro Guideline Development Tool [Software]. McMaster University (developed by Evidence Prime, Inc.), 2015.
190. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bulletin of the World Health Organization 1976;54(5):541-53.
191. Higgins JP, Altman DG, Sterne JA, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.
192. Johnson W, Onuma O, Owolabi M, Sachdev S. Stroke: a global response is needed. Bulletin of the World Health Organization 2016;94(9):634-634A.
193. Lang UE, Jockers-Scherübl MC, Hellweg R. State of the art of the neurotrophin hypothesis in psychiatric disorders: implications and limitations. Journal of Neural Transmission 2004;111(3):387-411.
194. Legg LA, Tilney R, Hsieh C, Wu S, Lundström E, Rudberg A, et al. Selective serotonin reuptake inhibitors for stroke recovery. Cochrane Database of Systematic Reviews 2019, Issue 11. Art. No: CD009286. [DOI: 10.1002/14651858.CD009286.pub3]
195. Li, X, Zhang C. Comparative efficacy of nine antidepressants in treating Chinese patients with post-stroke depression: a network meta-analysis. Journal of Affective Disorders 2020;266:540-8.
196. Lim CM, Kim SW, Park JY, Kim C, Yoon SH, Lee JK. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. Journal of Neuroscience Research 2009;87(4):1037-45.
197. Loubinoux I, Boulanouar K, Ranjeva JP, Carel C, Berry I, Rascol O, et al. Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks. Journal of Cerebral Blood Flow and Metabolism 1999;19(12):1365-75.
198. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 1959;22(4):719-48.
199. Mead GE, Graham C, Billot L, Näsman P, Lundström E, Lewis S, for FOCUS, AFFINITY and EFFECTS trialists. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials 2020;21(1):971. [DOI: https://doi.org/10.1186/s13063-020-04875-1]
200. Ming GL, Song H. Adult neurogenesis in the mammalian central nervous system. Annual Review of Neuroscience 2005;28:223-50.
201. Molnar FJ, Hutton B, Fergusson D. Does analysis using “last observation carried forward” introduce bias in dementia research? CMAJ 2008;179(8):751–3.
202. NHS. Side effects-selective serotonin reuptake inhibitors (SSRI). www.nhs.uk (accessed 10 August 2021).
203. Pälvimäki E-P, Laakso A, Kuoppamäki M, Syvälahti E, Hietala J. Up-regulation of beta l-adrenergic receptors in rat brain after chronic citalopram and fluoxetine treatments. Psychopharmacology 1994;115(4):543-6.
204. Pinto CB, Saleh Velez FG, Lopes F, de Toledo Piza PV, Dipietro L, Wang QM, et al. SSRI and motor recovery in stroke: reestablishment of inhibitory neural network tonus. Frontiers in Neuroscience 2017;11:637. [DOI: 10.3389/fnins.2017.00637]
205. The Cochrane Collaboration Review Manager 5 (RevMan 5). Version 5.4. The Cochrane Collaboration, 2020.
206. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis antidepressant treatments and animal models of depressive-like behaviour. Behavioural Pharmacology 2003;301:805-9.
207. Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behaviour. Behavioural Pharmacology 2007;18(5-6):391-418.
208. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Akl E, Guyatt GH on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.
209. Shin TK, Kang MS, Lee HY, Seo MS, Kim SG, Kim CD, et al. Fluoxetine and sertraline attenuate postischemic brain injury in mice. Korean Journal of Physiology and Pharmacology 2009;13(3):257-63.
210. Sterne JA, Egger M, Moher D, Boutron I, editor(s). Chapter 10: Addressing reporting biases. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.
211. Taupin P. Adult neurogenesis and neuroplasticity. Restorative Neurology and Neuroscience 2006;24(1):9-15.
212. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology 2014;14:135.
213. Wiltrout C, Lang B, Yan Y, Dempsey RJ, Vemuganti R. Repairing brain after stroke: a review on post-ischaemic neurogenesis. Neurochemistry International 2007;50(7-8):1028-41.
214. Xie Y, Liu PP, Lian YJ, Liu H-B, Kang J-S. The effect of selective serotonin reuptake inhibitors on cognitive function in patients with Alzheimer’s disease and vascular dementia: focusing on fluoxetine with long follow-up periods. Signal Transduction and Targeted Therapy 2019;4:30. [DOI: 10.1038/s41392-019-0064-7]
215. Yi ZM, Liu F, Zhai SD. Fluoxetine for the prophylaxis of post-stroke depression in patients with stroke: a meta-analysis. International Journal of Clinical Practice 2010;64(9):1310-7.
216. Zittel S, Weiller C, Liepert J. Citalopram improves dexterity in chronic stroke patients. Neurorehabilitation and Neural Repair 2008;22(3):311-4. [DOI: 10.1177/1545968307312173]
217. Legg LA, Tilney R, Hsieh CF, Wu S, Lundström E, Rudberg AS, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database of Systematic Reviews 2019, Issue 11. Art. No: CD009286. [DOI: 10.1002/14651858.CD009286.pub3]
218. Mead GE, Hankey GJ, Kutlubaev MA, Lee R, Bailey M, Hackett ML. Selective serotonin reuptake inhibitors (SSRIs) for stroke. Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No: CD009286. [DOI: 10.1002/14651858.CD009286]
219. Mead GE, Hsieh CF, Lee R, Kutlubaev MA, Claxton A, Hankey GJ, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No: CD009286. [DOI: 10.1002/14651858.CD009286.pub2]